Torrent Pharmaceuticals Limited share price

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shel…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNifty Next 50 Nifty 100 Nifty 500NSE: TORNTPHARMISIN INE685A01028

16 Oct 2026, 3:29 PM IST₹4,558.90▼ 25.20 (0.55%)

Market Cap₹ 1,73,406 Cr.
Current Price₹ 4,558.90
High / Low₹ 5,250 / 3,506
Stock P/E72.8
Book Value₹ 248
Dividend Yield0.83 %
ROCE9.1 %
ROE27.10 %
Face Value₹ 5.0

More figures (10)

EPS (TTM)₹ 62.60
Price / Book18.39
OPM25.0 %
Debt / Equity1.79
Sales growth (5Y)11.8 %
Profit growth (5Y)11.3 %
Promoter holding63.2 %
EV / EBITDA36.6
Beta0.14
All-time high₹ 5,250

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
TORNTPHARM	-5.27%	-8.60%	+9.70%	+18.41%	+29.01%	+33.57%	+24.02%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Torrent Pharmaceuticals Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹1,73,406 crore.
It trades at 72.8 times its last 12 months' earnings and 18.4 times book value.
Revenue grew 11.8% a year over the last 5 years, profit 11.3% a year.
Return on equity was 27.1% and return on capital employed 9.1% in the latest year.
Debt was 1.79 times shareholders' equity.
The share price is 13.2% below its 52-week high and up 29.0% over one year.
Promoters and insiders hold about 63.2%; institutions about 19.7%.

Pros

Strong return on equity: 26.3% on average over the last 3 years.
Pays a healthy dividend: about 60% of profit last year.
Institutional (FII + DII) holding has risen by 9.4 points over 3 years.

Cons

Borrowings are high at 1.79 times shareholders' equity.
Promoter holding has fallen by 10.47 points over 3 years, to 60.78%.
Trades at 18.4 times its book value.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Torrent Pharmaceuticals Limited

Employees: 18,258
Head office: Ahmedabad
NSE industry: Healthcare

HealthcareHealthcareDrug Manufacturers - Specialty & Generic

Part ofNifty Next 50 Nifty 100 Nifty 500

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	11.8
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
5.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
6.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
7.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
8.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
9.	Mankind Pharma	2,275.50	46.0	93,988	0.00	568	35.00	4,031	30.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
10.	Lupin	1,961.60	16.2	89,702	0.91	1,415	83.17	8,217	47.73	28.3	26.9	3.99	24.8	0.29	47.02	27,488	19.1
	Median: 35 Co.	1,860.20	33.0	31,766	0.33	846	24.47	7,440	21.59	16.4	16.8	4.93	17.5	0.25	53.40	27,104	13.4

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	2,591	2,660	2,732	2,745	2,859	2,889	2,809	2,959	3,178	3,302	3,303	4,197	4,921
YOY Sales Growth %		16.11%	9.67%	10.20%	10.34%	8.61%	2.82%	7.80%	11.16%	14.30%	17.59%	41.84%	54.85%
	1,800	1,835	1,863	1,862	1,955	1,950	1,895	1,995	2,146	2,219	2,215	2,841	3,257
Material Cost %	25%	25%	26%	25%	24%	23%	24%	25%	24%	24%	24%	24%	24%
Employee Cost %	19%	19%	18%	18%	19%	19%	20%	19%	19%	19%	20%	19%	18%
Other Expenses %	25%	25%	25%	25%	25%	25%	24%	24%	24%	24%	23%	25%	24%
Operating Profit	791	825	869	883	904	939	914	964	1,032	1,083	1,088	1,356	1,664
OPM %	31%	31%	32%	32%	32%	33%	33%	33%	32%	33%	33%	32%	34%
	34	26	-33	31	24	-16	33	-18	-37	-27	-13	-17	-12
Exceptional items			88					-24		-13	-10	-66	-21
Interest	103	91	80	80	75	64	57	56	56	48	45	236	305
Depreciation	191	201	213	203	197	198	199	201	201	204	206	508	593
Profit before tax	531	559	631	631	656	661	691	665	738	791	814	529	733
	29%	31%	30%	29%	30%	31%	27%	25%	26%	25%	22%	31%	23%
Current tax	94	120	106	142	126	156	153	184	201	233	244	166	254
Deferred tax	59	53	82	40	73	52	35	-17	-11	-33	-65	-1	-87
	378	386	443	449	457	453	503	498	548	591	635	364	566
Minority share												-25
Profit to shareholders	378	363	442	449	457			498	548	591	635	389	566
YOY Profit Growth %		23.72%	56.54%	56.45%	20.90%	17.36%	13.54%	10.91%	19.91%	30.46%	26.24%	-26.91%	3.28%
EPS in Rs	11.18	11.39	13.10	13.27	13.51	13.37	14.88	14.71	16.19	17.45	18.77	11.51	14.87
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	2,121	2,146	2,123	2,143	2,438	2,434	2,377	2,433	2,616	2,762	2,599	2,735	4,158
YOY Sales Growth %	9.73%	11.31%	14.32%	11.61%	14.95%	13.42%	11.96%	13.53%	7.30%	13.48%	9.34%	12.41%	58.94%
	1,384	1,410	1,422	1,427	1,539	1,513	1,490	1,565	1,637	1,690	1,599	1,732	2,585
Material Cost %	24%	24%	26%	25%	24%	22%	23%	24%	22%	22%	21%	21%	23%
Employee Cost %	17%	17%	17%	16%	17%	17%	17%	17%	17%	17%	18%	18%	16%
Other Expenses %	24%	24%	23%	25%	23%	23%	23%	23%	23%	22%	22%	25%	23%
Operating Profit	737	736	701	716	899	921	887	868	979	1,072	1,000	1,003	1,573
OPM %	35%	34%	33%	33%	37%	38%	37%	36%	37%	39%	38%	37%	38%
	11	15	-11	76	21	-7	3	15	-5	-27	-8	58	-21
Exceptional items								-24		-13	-10	-47	-21
Interest	90	77	69	67	64	54	48	47	45	37	34	225	293
Depreciation	183	192	191	195	189	190	191	190	187	189	191	197	575
Profit before tax	475	482	430	530	667	670	651	622	742	806	757	592	663
	32%	32%	31%	23%	30%	31%	25%	24%	26%	26%	24%	21%	26%
Current tax	82	83	75	82	117	139	125	160	198	220	230	72	266
Deferred tax	70	72	58	38	81	71	41	-12	-7	-11	-50	53	-95
	323	327	297	410	469	460	485	474	551	597	577	467	492
YOY Profit Growth %	-1.22%	20.22%	29.69%	87.21%	45.20%	40.67%	63.30%	15.61%	17.48%	29.78%	18.97%	-1.48%	-10.71%
EPS in Rs	9.55	9.65	8.78	12.12	13.86	13.60	14.33	14.00	16.28	17.64	17.04	13.80	12.94
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	6,002	7,673	7,939	8,005	8,508	9,620	10,728	11,516	13,980	15,723
YOY Sales Growth %		27.84%	3.47%	0.83%	6.28%	13.07%	11.52%	7.35%	21.40%
	4,653	5,689	5,769	5,520	6,077	6,778	7,360	7,795	9,421	10,532
Material Cost %	28%	29%	27%	27%	29%	28%	25%	24%	24%	24%
Employee Cost %	19%	18%	18%	18%	18%	17%	18%	19%	19%	19%
Other Expenses %	31%	27%	27%	24%	25%	25%	25%	24%	24%	24%
Operating Profit	1,349	1,984	2,170	2,485	2,431	2,842	3,368	3,721	4,559	5,191
OPM %	22%	26%	27%	31%	29%	30%	31%	32%	33%	33%
	299	57	122	57	197	45	58	23	-94	-69
Exceptional items		-357			-485		88	-24	-89	-110
Interest	308	504	451	358	255	333	354	252	385	634
Depreciation	409	618	654	658	662	707	808	795	1,119	1,511
Profit before tax	931	562	1,187	1,526	1,226	1,847	2,352	2,673	2,872	2,867
	27%	22%	14%	18%	37%	33%	30%	29%	26%	25%
Current tax	261	281	221	327	342	374	462	619	844
Deferred tax	-8	-155	-59	-53	107	228	234	143	-110
	678	436	1,025	1,252	777	1,245	1,656	1,911	2,138	2,156
Minority share									-25	-25
Profit to shareholders				1,252	777	1,245	1,656	1,911	2,163	2,181
YOY Profit Growth %		-35.69%	135.09%	22.15%	-37.94%	60.23%	33.01%	15.40%	11.88%
EPS in Rs	20.04	12.89	30.28	36.99	22.97	36.79	48.94	56.47	63.92	62.60
Dividend Payout %						69%	61%	57%	60%

Compounded Sales Growth

5 Years:: 12%
3 Years:: 13%
TTM:: 33%

Compounded Profit Growth

5 Years:: 11%
3 Years:: 20%
TTM:: 8%

Stock Price CAGR

5 Years:: 24%
3 Years:: 34%
1 Year:: 29%

Return on Equity

4 Years:: 25%
Last Year:: 27%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	4,248	5,762	6,168	6,451	6,742	7,695	8,533	9,682	10,712	12,254
YOY Sales Growth %		35.64%	7.05%	4.59%	4.51%	14.14%	10.89%	13.47%	10.64%
	3,340	4,149	4,251	4,254	4,642	5,230	5,643	6,107	6,658	7,606
Material Cost %	26%	27%	27%	26%	28%	28%	25%	23%	22%	22%
Employee Cost %	19%	18%	17%	17%	16%	16%	17%	17%	18%	17%
Other Expenses %	33%	28%	25%	23%	24%	24%	24%	23%	23%	23%
Operating Profit	908	1,613	1,917	2,197	2,100	2,465	2,890	3,575	4,054	4,648
OPM %	21%	28%	31%	34%	31%	32%	34%	37%	38%	38%
	332	382	237	118	204	82	91	32	18	2
Exceptional items								-24	-70	-91
Interest	294	481	430	339	236	298	303	213	341	589
Depreciation	384	579	607	610	602	672	761	760	764	1,152
Profit before tax	562	935	1,117	1,366	1,466	1,577	1,917	2,610	2,897	2,818
	14%	20%	16%	17%	32%	33%	29%	28%	24%	24%
Current tax	121	194	192	248	253	274	322	541	720
Deferred tax	-41	-4	-14	-20	222	251	238	181	-15
	482	745	939	1,138	991	1,052	1,357	1,888	2,192	2,133
YOY Profit Growth %		54.56%	26.04%	21.19%	-12.92%	6.16%	28.99%	39.13%	16.10%
EPS in Rs	14.24	22.03	27.73	33.62	29.30	31.07	40.10	55.79	64.75	61.42
Dividend Payout %						82%	75%	57%	59%

Compounded Sales Growth

5 Years:: 11%
3 Years:: 12%
TTM:: 24%

Compounded Profit Growth

5 Years:: 14%
3 Years:: 28%
TTM:: 8%

Stock Price CAGR

5 Years:: 24%
3 Years:: 34%
1 Year:: 29%

Return on Equity

4 Years:: 25%
Last Year:: 27%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	169	169	169	169
Reserves	6,029	6,687	7,421	8,219
	5,369	4,022	3,202	15,026
Long term borrowings	2,496	1,604	1,192	11,651
Short term borrowings	2,801	2,334	1,834	3,147
	3,445	4,182	4,197	20,898
Trade payables	1,679	2,089	1,820	2,358
Minority interest				9,196
Current liabilities	5,447	5,425	4,717	8,343
Total Liabilities	15,012	15,061	14,990	44,312
	3,482	3,593	3,865	5,394
Gross block	5,303	5,625	6,104	7,943
Accumulated depreciation	1,820	2,032	2,239	2,549
Goodwill & intangibles	5,427	4,921	4,602	28,453
CWIP	711	296	409	486
	10,819	11,171	10,716	38,432
Inventories	2,230	2,279	2,541	3,138
Trade receivables	1,944	1,844	1,866	3,031
Cash & equivalents	509	835	573	1,117
Current assets	5,314	5,611	5,623	9,392
Total Assets	15,012	15,061	14,990	44,312

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2,368	3,266	2,585	3,023
Profit for the year	1,245	1,656	1,911	2,163
Working capital changes	-18	418	-481	-342
Direct taxes paid	-398	-498	-603	-809
	-2,415	-168	-540	-12,712
Fixed assets purchased	-574	-433	-612	-677
Fixed assets sold	159	134	18	41
Investments purchased	-60		-12	-13
Investments sold	47	118	46	216
	77	-2,780	-2,298	10,151
Proceeds from borrowings	1,395			12,594
Repayment of borrowings	-972	-1,369	-926	-672
Interest paid	-303	-371	-262	-427
Dividends paid	-863	-1,015	-1,083	-1,289
Net Cash Flow	30	319	-253	461
Free Cash Flow	1,794	2,833	1,973	2,345

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	20.1%	25.4%	26.5%	27.1%
ROCE	22.8%	28.1%	28.5%	9.1%
Operating margin	22.6%	24.4%	25.9%	25.0%
Net margin	13.2%	15.7%	16.9%	15.7%
Debt / equity	0.87	0.59	0.42	1.79
Current ratio	0.98	1.03	1.19	1.13
Debtor days	75	64	60	80
Inventory days	288	298	322	325
Days payable	217	274	230	244
Cash conversion cycle	146	88	152	161
Working capital days	-5	6	29	28

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 60.78%
FIIs 17.22%
DIIs 13.46%
Public 8.54%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	71.25%	71.25%	71.25%	71.25%	68.31%	68.31%	68.31%	68.31%	68.31%	68.31%	68.31%	60.78%
	14.09%	14.14%	14.22%	14.46%	16.17%	16.31%	16.09%	15.92%	16.13%	16.18%	15.44%	17.22%
Foreign portfolio investors (Cat. I)	13.71%	13.72%	13.82%	14.12%	15.79%	15.90%	15.73%	15.52%	15.70%	15.74%	15.01%	16.69%
Foreign portfolio investors (Cat. II)	0.37%	0.42%	0.40%	0.34%	0.38%	0.41%	0.36%	0.40%	0.43%	0.44%	0.43%	0.53%
	7.21%	7.26%	7.27%	7.08%	8.35%	8.35%	8.65%	9.28%	9.14%	9.06%	9.83%	13.46%
Mutual funds	4.48%	4.46%	4.35%	3.69%	4.88%	5.03%	4.95%	5.12%	4.83%	4.45%	4.94%	8.82%
Insurance companies	1.96%	1.95%	2.00%	1.89%	1.70%	1.31%	1.62%	1.89%	1.72%	1.94%	2.20%	1.96%
Banks			0.01%							0.03%	0.02%	0.02%
Provident & pension funds	0.60%	0.67%	0.74%	1.32%	1.58%	1.80%	1.89%	2.09%	2.44%	2.49%	2.50%	2.32%
Alternative investment funds	0.07%	0.07%	0.07%	0.08%	0.09%	0.11%	0.08%	0.07%	0.06%	0.05%	0.07%	0.25%
	7.45%	7.36%	7.26%	7.21%	7.17%	7.03%	6.94%	6.49%	6.42%	6.45%	6.42%	8.54%
Retail (up to ₹2 lakh)	3.62%	3.55%	3.45%	3.37%	3.34%	3.26%	3.19%	2.82%	2.78%	2.75%	2.75%	4.55%
HNIs (above ₹2 lakh)	0.53%	0.53%	0.53%	0.97%	1.27%	1.25%	1.25%	1.25%	1.25%	1.36%	2.29%	2.40%
NRIs	0.18%	0.17%	0.17%	0.17%	0.16%	0.16%	0.16%	0.12%	0.12%	0.13%	0.12%	0.22%
Bodies corporate	0.40%	0.38%	0.39%	0.40%	0.43%	0.39%	0.36%	0.32%	0.30%	0.33%	0.29%	0.36%
IEPF	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.17%
No. of Shareholders	69,117	71,154	74,765	79,848	85,035	86,005	81,856	78,226	76,214	83,811	85,776	1,42,140

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Torrent Pharmaceuticals

Holder (above 1%)	Stake
Nps TrustPension fund	2.32%
HDFC MUTUAL FUNDMutual fund · see the fund house	1.14%
AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL FUNDMutual fund · see the fund house	1.12%
Kotak Debt HybridMutual fund	1.05%

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 8.82% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Results announced: 6 Nov 2026
Ex-dividend date: 29 May 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Torrent Pharmaceuticals Limited

What is the share price of Torrent Pharmaceuticals Limited today?

Torrent Pharmaceuticals Limited (TORNTPHARM) last traded at ₹4,558.90 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Torrent Pharmaceuticals Limited?

About ₹1,73,406 crore at the latest price.

What is the P/E ratio of Torrent Pharmaceuticals Limited?

About 72.8 times its earnings over the last 12 months.

Is Torrent Pharmaceuticals Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Torrent Pharmaceuticals Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Torrent Pharmaceuticals Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Torrent Pharmaceuticals Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Torrent Pharmaceuticals

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Torrent Pharmaceuticals Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next